PRACTICE SETTING
News
Videos
Resource Centers
Continuing Education
Community
Pharmacy school prepares us to join the workforce, but our dynamic and evolving profession demands that
we continue our education as lifelong learners.
In pursuit of filling knowledge gaps and extending our capacity to provide quality care for patients, we get
the opportunity to learn more about various disease states and the remedies employed to treat them.
During this time of learning through real-world experiences, it is inevitable that we will eventually encounter
various oddities and curiosities not discussed in school.
However, there are some non-infectious purposes for which antibiotics can be used.
Here are 6 non-infectious indications for antibiotics that you may not have learned about during pharmacy
school. As you read through them, note that potential toxicities and ecologic consequences of antimicrobial
use should always be considered prior to employing such therapy.
Minocycline is a tetracycline antibiotic that has been found to have anti-inflammatory, anti-apoptotic, and
neuroprotective effects.1 Animal and human data suggest that minocycline may provide benefit for patients
with acute stroke while imposing little risk.
2. Azithromycin for treating cystic fibrosis lung disease or preventing COPD exacerbations.
A 2015 review paper on azithromycin and cystic fibrosis concluded that available data support azithromycin
efficacy during the first year of administration, though the long-term benefits remain debated.2 In a review of
azithromycin for preventing chronic obstructive pulmonary disease (COPD) exacerbations, it was noted that
long-term use can reduce COPD exacerbations, but concerns over adverse effects have limited its use for
this indication.3
For more than 2 decades, tetracycline antibiotic doxycycline has been administered via the intrapleural
route in the management of malignant pleural effusion,4 and it continues to be used today for this purpose.
Both antimalarial agents hydroxychloroquine and chloroquine have immunomodulatory effects and been
Publications
used for more than 7 decades in the management of systemic lupus erythematous and rheumatoid
arthritis.5 Hydroxychloroquine is generally preferred over chloroquine because it has fewer gastrointestinal
and ocular adverse effects.
Both azole antifungal agents fluconazole and ketoconazole have been used to increase the concentrations
of the immunosuppressant agent tacrolimus.6,7 These increased tacrolimus concentrations result from
cytochrome P450 and p-glycoprotein drug-drug interactions.
Erythromycin is a macrolide antibiotic, a motilin receptor agonist, and a potent prokinetic, which decreases
gastric emptying time.8 Azithromycin is also a macrolide antibiotic and has been studied in gastroparesis.9
Although most evidence focuses on erythromycin, interest persists regarding its replacement with
azithromycin, since it has fewer drug-drug interactions, fewer gastrointestinal effects, less impact on the
QTc interval, and a longer half-life.
The views expressed in this article are those of the author and do not necessarily reflect the position or
policy of the Department of Veterans Affairs or the United States government.
References:
1. Vedantam S, Moller AR. Minocycline: a novel stroke therapy. J Neurol Stroke. 2015; 2(6): 00073.
2. Principi N, Blasi F, Esposito S. Azithromycin use in patients with cystic fibrosis. Eur J Clin Microbial Infect
Dis. 2015; 34(6):1071-1079.
3. Taylor SP, Sellers E, Taylor BT. Azithromycin for the prevention of COPD exacerbations: the good, bad
and ugly. Am J Med. 2015; epub ahead of print.
4. Robinson LA, Fleming WH, Galbraith TA. Intrapleural doxycycline control of malignant pleural effusions.
Ann Thorac Surg. 1993; 55(5):1115-1121.
5. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacologic properties of
hydroxychloroquine and chloroquine in the treatment of systemic lupus erythematous, rheumatoid arthritis
and related diseases. Inflammopharmacology. 2015; 23(5): 231-269.
8. Enweluzo C, Aziz F. Gastroparesis: a review of current and emerging treatment options. Clin Exp
Gastroenterol. 2013; 6: 161-165.
9. Potter TG, Snider KR. Azithromycin for the treatment of gastroparesis. Ann pharmacother. 2013; 47(3):
411-415.
Tweet your thoughts about this article @Pharmacy_Times
Join the conversation on the Pharmacy Times Facebook page
Sign up for our eNews to get the latest news and updates delivered to your inbox
Latest Issues
photo
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
ONCLive
OTCGuide
Specialty Pharmacy Times
Targeted Oncology
About Us
Careers
Contact Us
Feedback
Advertise With Us
Terms & Conditions
Privacy
Press Room
Intellisphere, LLC
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-257-0701